The DOI matches its Crossref record; 108 of the 114 references it cites were found in a registry or an index; 71 of the 125 sources its claims cite were checked for support.
The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease
Open accessAbstract
Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression. Rates are even higher when considering mental health symptoms, as nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms. Rates of these symptoms were much higher during periods of disease activity, more common in women than men, and more common in Crohn's disease than ulcerative colitis. There is robust evidence of the detrimental effects of comorbid depression and anxiety on the subsequent course of IBD based on longitudinal studies tracking outcomes over time. However, psychiatric disorders and IBD have bidirectional effects, with each affecting risk of the other. Elevated mental health concerns have been consistently associated with greater healthcare utilization and costs related to IBD. There is some signal that low resilience in adolescence could be a risk factor for developing IBD and that enhancing resilience may improve mental health and intestinal disease outcomes in IBD. Psychological therapies used to treat anxiety and depression occurring in the context of IBD have been shown to significantly improve the quality of life for persons with IBD and reduce anxiety and depression. There is less evidence in regard to the impact of psychotropic medications on mental health or disease outcomes in persons with IBD. There is consensus, however, that mental health must be addressed as part of comprehensive IBD care for children and adults. © 2023 The Author(s). Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
Overview
CoChat Summary
## TL;DR
This review summarizes evidence that mental health disorders and symptoms are more common in people with IBD, are bidirectionally linked with worse IBD disease course, and are associated with higher healthcare use and costs. It also concludes that integrated multidisciplinary care and psychological therapies are the most supported approaches, while evidence for psychotropic medications and some other interventions remains limited.
## Key findings
- Psychiatric disorders were reported to be 1.5–2 times more prevalent in persons with IBD than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression.
- Symptom burden is also high: nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms; rates were higher during disease activity, more common in women, and more common in Crohn’s disease than ulcerative colitis.
- Mental health concerns were linked to worse IBD outcomes. For example, in the Swiss IBD Cohort Study (n = 1,973), elevated depressive symptoms were associated with recurrence of active disease (aHR 3.55), surgery (aHR 2.16), primary nonresponse to therapy (aHR 1.91), and systemic corticosteroid therapy (aHR 1.58).
- Psychological therapies improved outcomes: CBT and mindfulness were reported to significantly improve quality of life and reduce anxiety/depression, with one RCT of IBD-tailored CBT reporting benefit for moderate-to-severe presentations (depression d = 0.48; anxiety d = 0.58); a mindfulness trial reported immediate post-treatment effects ranging from d = 0.56 to 1.27 and six-month effects of d = 0.45 to 1.38.
## Methods
- This paper is a narrative review / impact-report chapter synthesizing prior epidemiologic studies, cohort studies, systematic reviews/meta-analyses, and intervention studies on mental health and IBD.
- It draws on evidence from adults, children, and adolescents with IBD, including population-based databases, cohort studies, randomized controlled trials, and systematic reviews.
- The main analysis is qualitative synthesis of published evidence; the paper does not report a new primary study design of its own.
## Limitations
- The paper states that psychotropic medications have less evidence for effects on mental health or IBD outcomes than psychological therapies, and that there is little data on efficacy directly in IBD.
- The paper notes that very few studies have evaluated resilience and self-efficacy over time in IBD, limiting directionality.
- Evident from the text: much of the evidence summarized is from observational studies, small pilots, or heterogeneous samples, so causal conclusions are limited; the paper also explicitly notes some findings are based on uncontrolled comparator samples or studies with small sample size.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Valid · 3 Not valid · 43 Not checked · 7 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression.”
- Also stated in: § Risk of Mental Health Disorders and Symptoms in IBD · plain
“Epidemiologic studies have found that individuals with IBD have a higher incidence of diagnosed mental illnesses compared to matched controls, inclusive of depression (18.6 per 1,000 people; 95% CI: 14.2, 24.3 vs. 10.8 per 1,000; 95% CI: 9.26, 12.5), anxiety (25.0 per 1,000; 95% CI: 19.6, 32.0 vs. 16.3 per 1,000; 95% CI: 14.3, 18.6), bipolar illness (3.8 per 1,000; 95% CI: 2.29, 6.30 vs. 1.56 per”
§ The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease > Abstract Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression. Rates are even higher when considering mental health symptoms, as nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms. Rates of these symptoms were much higher during periods of disease activity, more common in women than men, and more common in Crohn’s disease than ulcerative colitis. There is robust evidence of the detrimental effects of comorbid depression and anxiety on the subsequent course of IBD based on longitudinal studies tracking outcomes over time. However, psychiatric disorders and IBD have bidirectional effects, with each affecting risk of the other. Elevated mental health concerns have been consistently associated with greater healthcare utilization and costs related to IBD. There is some signal that low resilience in adolescence could be a risk factor for developing IBD and that enhancing resilience may improve mental health and intestinal disease outcomes in IBD. Psychological therapies used to treat anxiety and depression occurring in the context of IBD have been shown to significantly improve the quality of life for persons with IBD and reduce anxiety and depression. There is less evidence in regard to the impact of psychotropic medications on mental health or disease outcomes in persons with IBD. There is consensus, however, that mental health must be addressed as part of comprehensive IBD care for children and adults. - Psychiatric disorders are 1.5–2 times more prevalent in persons with IBD than the general population, with prevalence rates of nearly 21% for diagnosed anxiety and 15% for depression, and yet they can go undetected. Youth with IBD have nearly double the risk of a psychiatric diagnosis, and sixfold the risk of depression.
What the sources say
- Partly supportedcites [2] Bernstein, 2019, Increased burden of psychiatric disorders in inflammatory bowel disease, Inflamm Bowel Dis sourceExperimental — accuracy not yet measured
The Prevalence section reports higher lifetime prevalence of depression, anxiety and bipolar disorder in the IBD cohort than in matched controls. But its adjusted prevalence ratios are 1.42, 1.24 and 1.45, respectively—not 1.5 to 2 times higher. The paper reports ratios nearer the claimed range for incidence, which is a different measure. (LLM, conf=0.90)
- Partly supportedcites [3] Irving, 2021, Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: Population-based cohort study, Evid Based Ment Health sourceExperimental — accuracy not yet measured
The Findings (Prevalence of mental health conditions; page not provided) show that depression and anxiety were generally more common in people with IBD than in matched controls. They do not support the claimed 1.5–2-fold prevalence: the reported comparisons are approximately 1.1–1.4-fold, and the difference in anxiety episodes for ulcerative colitis was not statistically significant. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Risk of Mental Health Disorders and Symptoms in IBD · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“The highest risk for a mental health concern has been seen in the first year after IBD diagnosis (hazard ratio [HR]: 1.4; 95% CI: 1.2, 1.6) (5), however, depression or anxiety can present at any time in the course of the illness.”
§ The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease > Risk of Mental Health Disorders and Symptoms in IBD
What the sources say
- Supportedcites [5] Ludvigsson, 2021, Association between inflammatory bowel disease and psychiatric morbidity and suicide: A Swedish nationwide population-based cohort study with sibling comparisons, J Crohns Colitis source
The Results (section 3.2.3, Vulnerable risk groups) state that overall psychiatric morbidity was highest during the first year after IBD diagnosis, with HR 1.4 and 95% CI 1.2–1.6. This matches the risk and timing attributed to the source. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, while still very uncommon, adults with IBD have a higher risk of suicidality compared to the general community (HR: 1.2, 1.4) (5).”
§ The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease > Risk of Mental Health Disorders and Symptoms in IBD
What the sources say
- Supportedcites [5] Ludvigsson, 2021, Association between inflammatory bowel disease and psychiatric morbidity and suicide: A Swedish nationwide population-based cohort study with sibling comparisons, J Crohns Colitis source
The Results (§3.2, page not available) report more suicide attempts in adults with IBD than in matched general-population reference individuals. The paper also reports a 1.2-fold increased risk of completed suicide; its reported HR range of 1.2–1.4 specifically describes suicide attempts across IBD types. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a study from Manitoba, Canada, which followed an IBD cohort of 247 individuals over three years, the risk of subsequent active IBD was increased sixfold with elevated depressive symptoms (OR: 6.27; 95% CI: 1.39, 28.2), and elevated symptoms of anxiety doubled the risk for active IBD (OR: 2.17; 95% CI: 1.01, 4.66) (21).”
§ The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease > The Bidirectional Influence of Mental Health and Disease Course in IBD
What the sources say
- Partly supportedcites [21] Marrie, 2021, The relationship between symptoms of depression and anxiety and disease activity in IBD over time, Inflamm Bowel Dis sourceExperimental — accuracy not yet measured
The Results report that participants with elevated anxiety symptoms had higher odds of active IBD on average (OR 2.17; 95% CI 1.01–4.66), matching the quoted estimate. They do not establish that anxiety predicted subsequent active IBD: the Results say that within-person elevations in anxiety over time were not associated with increased odds of active IBD. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“symptoms of anxiety and depression were more common for women than men, and for those with Crohn’s disease compared with ulcerative colitis (7).”
§ The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease > Risk of Mental Health Disorders and Symptoms in IBD
What the sources say
- Supportedcites [7] Barberio, 2021, Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis, Lancet Gastroenterol Hepatol source
The indexed passage (section and page not provided) reports that, within the same study populations, patients with Crohn’s disease had higher odds of both anxiety and depression symptoms than patients with ulcerative colitis (OR 1.2 for each). (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
72 more claims · 36 with their cited sources checked
Create a free account to see all 112 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 31
Citations
Cites
Felitti, V. J., Anda, R. F., Nordenberg, D., Williamson, D. F., Spitz, A. M., Edwards, V., Koss, M. P., & Marks, J. S. (1998) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(98)00017-8 · Cited by 18,943 · cited 1×
“Given the high prevalence of adverse childhood experiences overall (39), and in persons with IBD (40), resilience, in addition to depression, may be an important target for intervention in those with IBD.”
BackgroundChild abuse: Adolescent records vs. adult recall
Femina, D. D., Yeager, C. A., & Lewis, D. O. (1990) · Child Abuse & Neglect · doi:10.1016/0145-2134(90)90033-p · Cited by 8,820
Hayes, S. C. (2004) · Behavior Therapy · doi:10.1016/s0005-7894(04)80013-3 · Cited by 2,493 · cited 1×
“Acceptance and commitment therapy (ACT) is a third-wave psychological therapy grounded in cognitive, behavioural, and mindfulness strategies, which aims to decrease stress, improve psychological flexibility, and strengthen values-based action in day-to-day life (83).”
BackgroundSupporting the Health Care Transition From Adolescence to Adulthood in the Medical Home
White, P. H., Cooley, W. C., & TRANSITIONS CLINICAL REPORT AUTHORING GROUP, A. A. O. P. (2018) · Pediatrics · doi:10.1542/peds.2018-2587 · Cited by 1,417
Supporting the health care transition from adolescence to adulthood in the medical home
Cooley, W. C., Sagerman, P. J., & American Academy of Pediatrics, A. A. O. F. P. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0969 · Cited by 1,119
A-Tjak, J. G. L., Davis, M. L., Morina, N., Powers, M. B., Smits, J. A. J., & Emmelkamp, P. M. G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000365764 · Cited by 1,031 · cited 13×
“Participants had eight sessions on average, most commonly behavioral health (CBT, hypnotherapy) and nutrition.”
BackgroundInfluentialThe gut microbiota in anxiety and depression—A systematic review
Simpson, C. A., Diaz-Arteche, C., Eliby, D., Schwartz, O. S., Simmons, J. G., & Cowan, C. S. M. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101943 · Cited by 912 · cited 1×
“Reviews of depression and anxiety suggest inflammation and microbiota play a role in the development of these disorders, which may provide explanatory pathways relevant to IBD (13,14).”
BackgroundJoyce, S., Shand, F., Tighe, J., Laurent, S. J., Bryant, R. A., & Harvey, S. B. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017858 · Cited by 864
McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07757 · Cited by 800
Systematic Review and Meta-Analysis: Adolescent Depression and Long-Term Psychosocial Outcomes
Clayborne, Z. M., Varin, M., & Colman, I. (2019) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.07.896 · Cited by 787
Research works printed but not linked: 3
- Canada S, 2013, Canadian Community Health Survey: Mental Health, 2012
- Hungund, 2022, Psychological well-being of adolescents: Association with personality, J Positive School Psychol, 7, 6040
- Administration UFaD, 2011, FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with High Doses of Celexa (Citalopram Hydrobromide)
Cited by
Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease
West, J., Tan, K., Devi, J., Macrae, F., Christensen, B., & Segal, J. P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196292 · Cited by 24
Allemang, B. A., Browne, M., Barwick, M. A., Bollegala, N. P., Fu, N., Lee, K., Miatello, A., Dekker, E., Nistor, O.-I., Kohut, S. A., et al. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.114123 · Cited by 12
Self-citationXu, F. L., Xing, J., Fan, M., Zhu, Z., Chen, Y., Hu, W., & Zhou, Y. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s486974 · Cited by 6
Engineered spermidine-secreting Saccharomyces boulardii ameliorates colitis and colon cancer in mice
Mohaqiq, M., Palou, R., Li, R., Zhang, G., Vaishnav, H. T., Parweez, F., Moyana, T. N., Carragher, D. M., Cameron, D. W., Ramsay, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-16736-5 · Cited by 9
Self-citationMeta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
Goddard, Q., Markovinović, A., Ronksley, P. E., Seow, C., Ma, C., Shaheen, A., & Kaplan, G. G. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70492 · Cited by 5
Self-citation
Metadata
- Authors
- Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., Murthy, S. K., Peña-Sánchez, J.-N., Targownik, L. E., Jannati, N., Jones May, T., Akhtar Sheekha, T., Davis, T., Weinstein, J., Dahlwi, G., Im, J. H. B., Amankwah Osei, J., Rohatinsky, N., Ghandeharian, S., Goddard, Q., Gorospe, J., Gertsman, S., Louis, M., Wagner, R., Brass, C., Sanderson, R., & Bernstein, C. N.
- Affiliations
- University of Manitoba (CA)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- University of Calgary (CA)
- McGill University Health Centre (CA)
- Dalhousie University (CA)
- Crohn's and Colitis Canada (CA)
- University of Ottawa (CA)
- University of Saskatchewan (CA)
- Mount Sinai Hospital (CA)
- Division of Gastroenterology and Hepatology, University Health Network, University of Toronto , Toronto, Ontario , Canada
- Department of Community Health and Epidemiology, University of Saskatchewan , Saskatoon, Saskatchewan , Canada
- King Abdulaziz University (SA)
- McMaster University (CA)
- University of Alberta (CA)
- Muskoday First Nation , Saskatchewan , Canada
- James Smith Cree Nation , Saskatchewan , Canada
- Corresponding author
- Bernstein, Charles N
- ORCID
- Graff, Lesley A
- Geist, Rose
- Kuenzig, M Ellen
- Benchimol, Eric I
- Kaplan, Gilaad G
- Windsor, Joseph W
- Bitton, Alain
- Coward, Stephanie
- Jones, Jennifer L
- Lee, Kate
- Murthy, Sanjay K
- Peña-Sánchez, Juan-Nicolás
- Targownik, Laura E
- Jannati, Nazanin
- Dahlwi, Ghaida
- Im, James H B
- Rohatinsky, Noelle
- Goddard, Quinn
- Gorospe, Julia
- Gertsman, Shira
- Bernstein, Charles N
- Venue
- Journal of the Canadian Association of Gastroenterology
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-09-01
- Volume
- 6
- Issue
- Supplement_2
- Pages
- S64-S75
- ISSN
- 2515-2084 (ISSN-L)
- 2515-2092
- PMC
- PMC10478810
- OpenAlex
- W4386457006
- Cited by
- 30
- References
- 114
- Citations by year
- 2026: 14 · 2025: 8 · 2024: 7 · 2023: 1
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Canadian Association of Gastroenterology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- AbbVie Corporation
- Janssen Canada
- Pfizer Canada
- Bristol-Myers Squibb Canada
- Amgen Canada
- Takeda Foundation
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- inflammatory bowel disease, mental health, depression, anxiety, psychiatric comorbidity, Crohn's disease, ulcerative colitis, disease activity, health care utilization, health care costs, resilience, psychotherapy, psychotropic drugs, quality of life, bidirectional comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1093/jcag/gwad012
- The paper
- Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., Murthy, S. K., Peña-Sánchez, J.-N., Targownik, L. E., Jannati, N., Jones May, T., Akhtar Sheekha, T., Davis, T., Weinstein, J., Dahlwi, G., . . . Bernstein, C. N. (2023). The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology. https://doi.org/10.1093/jcag/gwad012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.